电子家族健康史工具识别与管理结直肠癌风险升高患者:随机对照试验方案
本研究为正在进行的随机对照试验,在退伍军人事务部初级保健机构中,将初级保健提供者随机分为立即干预组或等待名单对照组,评估基于网络的家族健康史采集工具MeTree及决策支持平台能否提高结直肠癌风险一致性筛查转诊率。主要结局为通过病历审查获得的风险一致性结直肠癌筛查转诊率,次要结局包括患者完成风险管理建议和遗传咨询转诊,并开展经济分析和提供者体验评估。
要点
- 约3-10%人群因家族史而结直肠癌风险升高,需要更频繁或强化的筛查。
- 高危人群中接受指南一致性照护的比例低于50%。
- MeTree同时提供面向患者和提供者的决策支持报告。
核心结论
- 该试验将评估患者采集的家族健康史结合决策支持在大型医疗系统(如退伍军人事务部)中促进风险适宜筛查的可行性和有效性。
研究设计与样本
- 正在进行的随机对照试验,杜伦退伍军人事务医疗系统和麦迪逊退伍军人事务医疗中心的初级保健提供者被随机分为立即干预组或等待名单对照组。
- 退伍军人纳入标准为分配给已入组提供者、有即将到来的初级保健预约、且无使其结直肠癌风险升高的状况(如个人史、腺瘤性息肉或炎症性肠病)。
- 近期接受过下消化道内镜(如结肠镜检查、乙状结肠镜检查)者被排除。
- 立即干预组患者将家族健康史信息录入基于网络的平台MeTree,该平台提供面向患者和提供者的决策支持报告;等待名单对照组患者在知情同意后12个月访问MeTree。
主要发现
- 主要结局为通过病历审查获得的风险一致性结直肠癌筛查转诊率。
- 次要结局包括患者完成风险管理建议(如结肠镜检查)和遗传咨询转诊。
- 将开展经济分析以及提供者对MeTree临床决策支持建议体验的评估,以在干预被证实有效时为未来实施工作提供信息。
关键数值与推荐
- 约3-10%的人群因家族史而结直肠癌风险升高,需要更频繁或强化的筛查。
- 高危人群中接受指南一致性照护的比例低于50%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Colorectal cancer is the fourth most commonly diagnosed cancer in the United States. Approximately 3-10% of the population has an increased risk for colorectal cancer due to family history and warrants more frequent or intensive screening. Yet, < 50% of that high-risk population receives guideline-concordant care. Systematic collection of family health history and decision support may improve guideline-concordant screening for patients at increased risk of colorectal cancer. We seek to test the effectiveness of a web-based, systematic family health history collection tool and decision support platform (MeTree) to improve risk assessment and appropriate management of colorectal cancer risk among patients in the Department of Veterans Affairs primary care practices. METHODS: In this ongoing randomized controlled trial, primary care providers at the Durham Veterans Affairs Health Care System and the Madison VA Medical Center are randomized to immediate intervention or wait-list control. Veterans are eligible if assigned to enrolled providers, have an upcoming primary care appointment, and have no conditions that would place them at increased risk for colorectal cancer (such as personal history, adenomatous polyps, or inflammatory bowel disease). Those with a recent lower endoscopy (e.g. colonoscopy, sigmoidoscopy) are excluded. Immediate intervention patients put their family health history information into a web-based platform, MeTree, which provides both patient- and provider-facing decision support reports. Wait-list control patients access MeTree 12 months post-consent. The primary outcome is the risk-concordant colorectal cancer screening referral rate obtained via chart review. Secondary outcomes include patient completion of risk management recommendations (e.g. colonoscopy) and referral for genetic consultation. We will also conduct an economic analysis and an assessment of providers' experience with MeTree clinical decision support recommendations to inform future implementation efforts if the intervention is found to be effective. DISCUSSION: This trial will assess the feasibility and effectiveness of patient-collected family health history linked to decision support to promote risk-appropriate screening in a large healthcare system such as the Department of Veterans Affairs. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02247336 . Registered on 25 September 2014.
引用
- Goldstein KM, Fisher DA, Wu RR, et al. An electronic family health history tool to identify and manage patients at increased risk for colorectal cancer: protocol for a randomized controlled trial. Trials. 2019. PMID: 31590688. doi:10.1186/s13063-019-3659-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。